DoD Peer Reviewed Alzheimer’s Transforming Care Award
ID: 353151Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Peer Reviewed Alzheimer’s Transforming Care Award (TrCA) to support innovative research aimed at improving the quality of life for individuals with Alzheimer's disease and related dementias (AD/ADRD). The program seeks projects that address critical unmet needs in dementia care, focusing on person-centered approaches that reduce caregiver stress and enhance community support, while emphasizing cultural competence and diversity in research populations. With an estimated total funding of $4.4 million and the expectation of awarding three grants, interested applicants must submit pre-applications by May 22, 2024, and full applications by June 20, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Defense's (DOD) FY24 Peer Reviewed Alzheimer’s Transforming Care Award, under the Congressionally Directed Medical Research Programs, aims to fund innovative research that addresses the needs of individuals with Alzheimer's disease and related dementias (AD/ADRD). With a total funding allocation of $15 million for FY24, the program prioritizes person-centered projects that enhance quality of life, reduce caregiver stress, and improve support for affected communities. Key submission deadlines include the pre-application on May 22, 2024, and full applications by June 20, 2024. Eligible applicants include both extramural and intramural organizations, with a focus on fostering community collaboration in research efforts. Projects should involve innovative strategies addressing gaps in dementia care, emphasizing cultural competence and diversity in study populations. Important elements of the award criteria include the necessity for preliminary data, plans for meaningful community engagement, and specified outcomes that demonstrate potential for real-world application. The proposed research must be non-incremental, providing transformative insights into AD/ADRD care. Applications will undergo rigorous peer review, assessing impact, feasibility, ethical considerations, and the potential to significantly advance knowledge and practices in the field.
    Similar Opportunities
    Toxic Exposures Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Toxic Exposures Translational Research Award (TRA) to support research on adverse health outcomes related to military toxic exposures. This grant aims to facilitate translational research that bridges basic science and clinical applications, focusing on developing diagnostics, treatment strategies, and understanding exposure mechanisms to improve health care for service members and their families. With an estimated total program funding of $12.8 million and the expectation of awarding six grants, applicants must submit a pre-application by August 13, 2024, followed by a full application due by November 7, 2024. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Toxic Exposures Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Toxic Exposures Clinical Trial Award under the Toxic Exposures Research Program (TERP). This grant aims to support the rapid implementation of clinical trials that address health outcomes related to military-related toxic exposures, with a focus on prevention, treatment, and management of associated symptoms and diseases. The program emphasizes the importance of collaboration between the Department of Defense and the Department of Veterans Affairs, seeking proposals that align with specific program goals and topic areas, such as neurotoxin exposure and Gulf War Illness. The total estimated funding for this initiative is $10.4 million, with applications due by November 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD VRP, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Vision Translational Research Award (VRP TRA) to support innovative translational research aimed at advancing the prevention, diagnosis, and treatment of eye injuries and visual dysfunction associated with military service. This grant opportunity encourages projects that establish a clear path for transforming promising discoveries into clinical applications, including new drugs and devices, with a focus on collaboration with regulatory experts to facilitate the approval process. With an estimated total program funding of $1.6 million and the expectation of one award, interested applicants must submit a pre-application by July 11, 2024, followed by a full application by November 8, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD VRP, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the FY24 Vision Clinical Trial Award to fund innovative clinical trials aimed at addressing eye injuries and visual dysfunctions related to military service. This grant opportunity supports early-phase clinical trials that evaluate new products, pharmacologic agents, and devices, with a focus on improving treatment outcomes for service-connected visual impairments. With an estimated total program funding of $2.56 million and an anticipated award amount of up to $1.6 million per application, interested applicants must submit their pre-applications by July 11, 2024, and full applications by November 8, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Toxic Exposures Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Toxic Exposures Investigator-Initiated Research Award (TERP IIRA) to support research addressing health outcomes related to military-related toxic exposures. This grant aims to fund studies that contribute significantly to understanding and improving patient care for diseases associated with such exposures, encompassing all research phases from basic laboratory studies to translational research involving human subjects and animal models. With an estimated total program funding of $3.2 million and the expectation of awarding four grants, interested applicants must submit pre-applications by August 13, 2024, and full applications by November 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment or renewal of Alzheimer's Disease Research Centers (ADRCs) through Grant Opportunity RFA-AG-24-001. This initiative aims to foster multidisciplinary collaboration and resource sharing among institutions dedicated to researching Alzheimer's Disease (AD) and related dementias (ADRD), with a focus on enhancing diverse perspectives in research. The program will provide a total of $32 million for seven awards in FY 2024, increasing to $65 million for 14 awards in both FY 2025 and FY 2026, with a maximum project budget of $2.925 million per year and a project period of up to five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for September 26, 2025.
    DOD Glioblastoma, Resource Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Resource Development Award, aimed at enhancing research capabilities for glioblastoma, a malignant brain tumor. This grant supports the development of preclinical model systems that improve the understanding and treatment of glioblastoma, with a focus on innovative approaches such as animal models, organoids, and patient-derived xenografts. With a total funding pool of $4 million, the program anticipates awarding up to five grants, each capped at $500,000 over three years. Interested applicants must submit a pre-application by November 6, 2024, followed by a full application due by November 20, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" aimed at developing a diverse and interdisciplinary workforce for translational research in this critical health area. The initiative invites eligible institutions to create training programs for predoctoral and postdoctoral researchers, focusing on enhancing skills in data science, disease biology, and drug discovery, while not permitting independent clinical trials. With an anticipated budget of approximately $2.7 million annually for 3-5 awards over fiscal years 2025-2027, applications are due by September 25, 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.